Prevention of Colorectal Cancer in Inflammatory Bowel Disease Using Advanced Technologies

  • Noa Krugliak Cleveland
  • Jami A. Kinnucan
  • David T. Rubin
Part of the Clinical Gastroenterology book series (CG)


The risk of colorectal cancer (CRC) among patients with inflammatory bowel disease (IBD) has been well described. The increased risk has been attributed to chronic mucosal inflammation, associated with early disease onset, increased disease duration, extensive mucosal involvement, and concomitant primary sclerosing cholangitis (PSC). Because of this risk, prevention strategies have been recommended and the primary approach to such prevention has been colonoscopic assessment of the mucosa in search of precancerous or early-stage cancerous lesions. Recent developments of advanced visualization techniques such as high-definition colonoscopes and dye-spray chromoendoscopy have provided new options for our approach to prevention. Due to the fact that we now have better visualization techniques, the approach has shifted away from random nontargeted sampling biopsies toward targeted biopsies, active surveillance, and segmental or subtotal resections. In this chapter, we describe the evolving evidence related to cancer prevention in chronic colitis, with an emphasis on newer technologies and how they have changed the approach to detection and follow-up of neoplasia. We propose a rational approach to the incorporation of selective chromoendoscopy and outline the evidence gaps for future study and guideline development.


Ulcerative colitis Crohn’s disease Colorectal cancer Dysplasia Neoplasia Surveillance High definition colonoscopy Chromoendoscopy Narrow band imaging 


  1. 1.
    Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease. Cancer. 2001;91:854–62.CrossRefPubMedGoogle Scholar
  4. 4.
    Choi C-HR, Rutter MD, Askari A, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol. 2015;110:1022–34.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Askling J, Dickman PW, Ekbom A, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356–62.CrossRefPubMedGoogle Scholar
  6. 6.
    Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000;14:145–54.CrossRefPubMedGoogle Scholar
  7. 7.
    Nuako KW, Ahlquist DA, Mahoney DW, et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology. 1998;115:1079–83.CrossRefPubMedGoogle Scholar
  8. 8.
    Velayos FS, Loftus EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130:1941–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med. 1990;323:1228–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Heuschen UA, Hinz U, Allemeyer EH, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology. 2001;120:841–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099–105.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case–control study. Clin Gastroenterol Hepatol. 2013; 11:1601–8.e4.Google Scholar
  15. 15.
    Claessen M, Lutgens M, van Buuren H, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis. 2009;15:1331–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Torres J, de Chambrun GP, Itzkowitz S, et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:497–508.CrossRefPubMedGoogle Scholar
  17. 17.
    Marelli L, Xirouchakis E, Kalambokis G, et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut. 2011;60:1224–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Broomé U, Löfberg R, Lundqvist K, et al. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum. 1995;38:1301–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Bernstein C, Shanahan F, Weinstein W. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994;343:71–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Gumaste V, Sachar D, Greenstein A. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992;33:938–41.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–21.CrossRefPubMedGoogle Scholar
  22. 22.
    Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125:1311–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015;81:489–501.CrossRefPubMedGoogle Scholar
  24. 24.
    Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Gyde S, Prior P, Macartney J, et al. Malignancy in Crohn’s disease. Gut. 1980;21:1024–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Greenstein AJ, Sachar DB, Smith H, et al. A comparison of cancer risk in Crohn’s disease and ulcerative colitis. Cancer. 1981;48:2742–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Ekbom A, Adami H, Helmick C, et al. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet. 1990;336:357–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Gillen C, Walmsley R, Prior P, et al. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35:1590–2.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Greenstein A, Sachar D, Pucillo A, et al. Cancer in Crohn’s disease after diversionary surgery: a report of seven carcinomas occurring in excluded bowel. Am J Surg. 1978;135:86–90.CrossRefPubMedGoogle Scholar
  30. 30.
    Connell W, Sheffield J, Kamm M, et al. Lower gastrointestinal malignancy in Crohn’s disease. Gut. 1994;35:347–52.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Yamazaki Y, Ribeiro MB, Sachar DB, et al. Malignant colorectal strictures in Crohn’s disease. Am J Gastroenterol. 1991;86(7):882–5.Google Scholar
  32. 32.
    Sigel JE, Petras RE, Lashner BA, et al. Intestinal adenocarcinoma in Crohn’s disease: a report of 30 cases with a focus on coexisting dysplasia. Am J Surg Pathol. 1999;23:651–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Adami H-O, Bretthauer M, Emilsson L, et al. The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut. 2016;65:889–93.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53:v1–16.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Eaden J, Mayberry J. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51:v10–2.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–85.CrossRefPubMedGoogle Scholar
  37. 37.
    Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale – update based on new evidence. Gastroenterology. 2003;124:544–60.CrossRefPubMedGoogle Scholar
  38. 38.
    Rubin DT. Why it’s time for updated U.S. colorectal cancer prevention guidelines in inflammatory bowel disease. Gastrointest Endosc. 2014;80:849–51.CrossRefPubMedGoogle Scholar
  39. 39.
    Odze RD, Farraye FA, Hecht JL, et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol. 2004;2:534–41.CrossRefPubMedGoogle Scholar
  40. 40.
    Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999;117:1288–94.CrossRefPubMedGoogle Scholar
  41. 41.
    Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999;117:1295–300.CrossRefPubMedGoogle Scholar
  42. 42.
    Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60:334–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Rubin DT, Rothe JA, Hetzel JT, et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65:998–1004.CrossRefPubMedGoogle Scholar
  44. 44.
    Pekow JR, Hetzel JT, Rothe JA, et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010;16:1352–6.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Yaeger R, Shah MA, Miller VA, et al. Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology. 2016;151(2):278–87.CrossRefPubMedGoogle Scholar
  46. 46.
    Krugliak Cleveland N, Colman RJ, Rodriquez D, et al. Surveillance of IBD using high definition colonoscopes does not miss adenocarcinoma in patients with low-grade dysplasia. Inflamm Bowel Dis. 2016;22:631–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Mooiweer E, van der Meulen-de Jong A, Ponsioen C, et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am J Gastroenterol. 2015;110:1014–21.CrossRefPubMedGoogle Scholar
  48. 48.
    Blonski W, Kundu R, Furth EF, et al. High-grade dysplastic adenoma-like mass lesions are not an indication for colectomy in patients with ulcerative colitis. Scand J Gastroenterol. 2008;43:817–20.CrossRefPubMedGoogle Scholar
  49. 49.
    Devlin SM, Melmed GY, Irving PM, et al. Recommendations for quality colonoscopy reporting for patients with inflammatory Bbowel disease: results from a RAND appropriateness panel. Inflamm Bowel Dis. 2016;22:1418–24.CrossRefPubMedGoogle Scholar
  50. 50.
    Rubin DT, Krugliak Cleveland N, Rodriquez DM. Outcomes of colitis-associated dysplasia after referral from the community to a tertiary center. Gastrointest Endosc. 2016;84(6):1078–9.Google Scholar
  51. 51.
    Naymagon S, Marion JF. Surveillance in inflammatory bowel disease: chromoendoscopy and digital mucosal enhancement. Gastrointest Endosc Clin N Am. 2013;23:679–94.CrossRefPubMedGoogle Scholar
  52. 52.
    Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992;103:1611–20.CrossRefPubMedGoogle Scholar
  53. 53.
    Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634–48.CrossRefPubMedGoogle Scholar
  54. 54.
    Rodriguez SA, Eisen GM. Surveillance and management of dysplasia in ulcerative colitis by U.S. gastroenterologists: in truth, a good performance. Gastrointest Endosc. 2007;66:1070.CrossRefPubMedGoogle Scholar
  55. 55.
    Van Den Broek FJ, Stokkers PC, Reitsma JB, et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol. 2014;109:715–22.CrossRefPubMedGoogle Scholar
  56. 56.
    Meijs S, Gardenbroek TJ, Sprangers MA, et al. Health-related quality of life and disability in patients with ulcerative colitis and proctocolectomy with ileoanal pouch versus treatment with anti-TNF agents. J Crohns Colitis. 2014;8:686–92.CrossRefPubMedGoogle Scholar
  57. 57.
    Krugliak Cleveland N, Rodriquez D, Hirsch A, et al. Subtotal or segmental colectomy is safe in patients with dysplasia and IBD. Presented at AIBD 2015, Orlando. 2015.Google Scholar
  58. 58.
    Subramanian V, Ragunath K. Advanced endoscopic imaging: a review of commercially available technologies. Clin Gastroenterol Hepatol. 2014; 12:368–376.e1.Google Scholar
  59. 59.
    Ignjatovic A, East JE, Subramanian V, et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol. 2012;107:885–90.CrossRefPubMedGoogle Scholar
  60. 60.
    Van Den Broek FJ, Fockens P, van Eeden S, et al. Narrow-band imaging versus high-definition endoscopy for the diagnosis of neoplasia in ulcerative colitis. Endoscopy. 2011;43:108–15.CrossRefPubMedGoogle Scholar
  61. 61.
    Pellisé M, López-Cerón M, de Miguel CR, et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc. 2011;74:840–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Subramanian V, Ramappa V, Telakis E, et al. Comparison of high definition with standard white light endoscopy for detection of dysplastic lesions during surveillance colonoscopy in patients with colonic inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:350–5.CrossRefPubMedGoogle Scholar
  63. 63.
    Mohammed N, Kant P, Abid F, et al. 446 High definition white light endoscopy (HDWLE) versus high definition with chromoendoscopy (HDCE) in the detection of dysplasia in long standing ulcerative colitis: a randomized controlled trial. Gastrointest Endosc. 2015; 81:AB148.Google Scholar
  64. 64.
    Deepak P, Hanson GJ, Fletcher JG, et al. Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. Gastrointest Endosc. 2016;83:1005–12.CrossRefPubMedGoogle Scholar
  65. 65.
    Krugliak Cleveland N, Huo D, Sadiq F, et al. Long-term follow-up of polypoid dysplasia and assessment of peri-polyp biopsies of flat mucosa in patients with IBD-colitis. Gastroenterology. 2016;150(4):S574Google Scholar
  66. 66.
    Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103:2342–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Marion JF, Waye JD, Israel Y, et al. Chromoendoscopy is more effective than standard colonoscopy in detecting dysplasia during longterm surveillance of patients with colitis. Clin Gastroenterol Hepatol. 2016;14:713–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology 2015; 148:639–51.e28.Google Scholar
  69. 69.
    Kaltenbach T. In: Rubin DT, editor. 2016.Google Scholar
  70. 70.
    Shapira Z, Feldman L, Lavy R, et al. Bowel preparation: comparing metabolic and electrolyte changes when using sodium phosphate/polyethylene glycol. Int J Surg (London, England). 2010;8:356–8.CrossRefGoogle Scholar
  71. 71.
    FDA drug safety communication: serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. The U.S. Food and Drug Administration Web site. Updated 2 Mar 2016. Accessed 17 Sept 2016.
  72. 72.
    Davies J, Burke D, Olliver JR, et al. Methylene blue but not indigo carmine causes DNA damage to colonocytes in vitro and in vivo at concentrations used in clinical chromoendoscopy. Gut. 2007;56:155–6.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Olliver JR, Wild CP, Sahay P, et al. Chromoendoscopy with methylene blue and associated DNA damage in Barrett’s oesophagus. Lancet. 2003;362:373–4.CrossRefPubMedGoogle Scholar
  74. 74.
    Toxicology and carcinogenesis studies of methylene blue trihydrate (Cas No. 7220-79-3) in F344/N rats and B6C3F1 mice (gavage studies). National Toxicology Program technical report series. 2008:1–224.Google Scholar
  75. 75.
    Piscatelli N, Hyman N, Osler T. Localizing colorectal cancer by colonoscopy. Arch Surg (Chicago, IL: 1960). 2005;140:932–5.Google Scholar
  76. 76.
    Tsai TC, Chao CM, Lai CC. Green urine. QJM. 2012;105:1133.CrossRefPubMedGoogle Scholar
  77. 77.
    Buchner AM, Ma GK, Ginsberg GG, et al. Su2070 Chromoendoscopy-guided probe based confocal laser endomicroscopy: a novel approach for dysplasia evaluation in IBD surveillance. Gastroenterology. 2016;150(4):S627.CrossRefGoogle Scholar
  78. 78.
    Buchner AM. Challenges in detection and real-time diagnosis of dysplasia in Crohn’s colitis: the search still continues. Gastrointest Endosc. 2016;83:972–4.CrossRefPubMedGoogle Scholar
  79. 79.
    Longcroft-Wheaton GR, Higgins B, Bhandari P. Flexible spectral imaging color enhancement and indigo carmine in neoplasia diagnosis during colonoscopy: a large prospective UK series. Eur J Gastroenterol Hepatol. 2011;23:903–11.CrossRefPubMedGoogle Scholar
  80. 80.
    Iacucci M, Gui X, Akinola O, et al. 625 Real time histology at endoscopy – virtual electronic chromoendoscopy and probe confocal laser endomicroscopy can assess fine details of inflammatory changes in ulcerative colitis patients. Gastroenterology. 2016;150(4):S129.Google Scholar
  81. 81.
    Goetz M, Wang TD. Molecular imaging in gastrointestinal endoscopy. Gastroenterology. 2010;138:828–33.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30–December 1, 2002. Gastrointest Endosc. 2003;58:S3–43.Google Scholar
  83. 83.
    Bronner MP, O’Sullivan JN, Rabinovitch PS, et al. Genomic biomarkers to improve ulcerative colitis neoplasia surveillance. Am J Pathol. 2008;173:1853–60.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Nathanson JW, Yadron NE, Farnan J, et al. p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn’s disease. Dig Dis Sci. 2008;53:474–80.CrossRefPubMedGoogle Scholar
  85. 85.
    Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008;103:2862–70.CrossRefPubMedGoogle Scholar
  86. 86.
    Shah SA, Rubin DT, Farraye FA. Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease. Curr Gastroenterol Rep. 2014;16:407.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Noa Krugliak Cleveland
    • 1
  • Jami A. Kinnucan
    • 2
  • David T. Rubin
    • 3
  1. 1.Department of Medicine, Inflammatory Bowel Disease CenterUniversity of Chicago MedicineChicagoUSA
  2. 2.Department of MedicineUniversity of Michigan Health SystemsAnn ArborUSA
  3. 3.Department of Medicine, Inflammatory Bowel Disease CenterUniversity of Chicago MedicineChicagoUSA

Personalised recommendations